Radiation-induced mutant gene products (None)

Radiation-induced mutant gene products refer to the diverse and heterogeneous array of proteins and peptides that result from genetic mutations caused by exposure to ionizing radiation. This term does not describe a single, well-defined molecular entity but rather a broad category of altered gene products, including neoantigens, which vary significantly depending on the specific DNA damage sustained (Barker et al., Nature Reviews Cancer, 2015). In clinical oncology, these products are significant because they can serve as novel epitopes for the immune system, a phenomenon often exploited in combination therapies where radiotherapy is used to enhance the efficacy of immune checkpoint inhibitors (Rodriguez-Ruiz et al., Trends in Immunology, 2018). Because the mutations are stochastic and unique to each individual or tumor region, they do not represent a standardized therapeutic target for small molecules or monoclonal antibodies. Instead, therapeutic strategies focus on specific recurrent mutations associated with radiation, such as RET/PTC rearrangements in post-Chernobyl thyroid cancer, or on broad immune activation against the resulting neoantigen pool (Nikiforov, Modern Pathology, 2008). Consequently, while these products are central to the pathology of radiation-induced diseases, the term itself is a descriptive classification rather than a distinct, druggable target.

Other names

Radiation-induced neoantigensRadiation-associated mutant proteinsRadiation-induced antigensRadiation-induced mutations

Not applicable